Literature DB >> 6237177

Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease.

E S Garnett, G Firnau, C Nahmias, R Carbotte, G Bartolucci.   

Abstract

Striatal glucose consumption was measured by positron emission tomography in 4 male patients, aged 16-27, suffering from Huntington's disease and in 3 age-matched control subjects. Symptoms had been present for 3 years or less; they were mainly psychiatric. Two of the patients had no chorea although the time taken to initiate a movement was prolonged and there was some reduction in the speed at which movements could be executed. Caudate atrophy was absent or minimal by CAT scan yet striatal glucose consumption was markedly reduced in all of the patients. It is suggested that striatal glucose consumption is largely determined by the functional integrity of spiny neurones in the striatum.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6237177     DOI: 10.1016/0022-510x(84)90087-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

Review 1.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  Differential effect of Huntington's and Parkinson's diseases in programming motor sequences of varied lengths.

Authors:  L Yágüez; H W Lange; V Hömberg
Journal:  J Neurol       Date:  2005-07-27       Impact factor: 4.849

3.  Deficits in stepping response time are associated with impairments in balance and mobility in people with Huntington disease.

Authors:  Allon Goldberg; Stacey L Schepens; Shawna M E Feely; James Y Garbern; Lindsey J Miller; Carly E Siskind; Gerry E Conti
Journal:  J Neurol Sci       Date:  2010-11-15       Impact factor: 3.181

4.  6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys.

Authors:  D J Doudet; H Miyake; R T Finn; C A McLellan; T G Aigner; R Q Wan; H R Adams; R M Cohen
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

5.  Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats.

Authors:  Kiyoshi Kyono; Tadayuki Takashima; Yumiko Katayama; Toshiyuki Kawasaki; Riyo Zochi; Maki Gouda; Yasuhiro Kuwahara; Kazuhiro Takahashi; Yasuhiro Wada; Hirotaka Onoe; Yasuyoshi Watanabe
Journal:  EJNMMI Res       Date:  2011-11-10       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.